A previous study demonstrated that tumor sphericity, measured from breast DCE-MRI during neoadjuvant therapy, is predictive of pathologic complete response and adds value to a predictive model based on functional tumor volume (FTV) alone. This study further explores the additive value of alternative radiomic shape features by breast cancer subtype. A subset of shape features were selected using visually assessed MRI morphological patterns as guidance. The analysis of treatment response prediction was conducted retrospectively using data from the multi-center neoadjuvant I-SPY 2 TRIAL. Improved predictive performance when adding shape features was observed at both pre-treatment and early treatment time points.
This abstract and the presentation materials are available to members only; a login is required.